RecruitingPhase 4NCT06668389

Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial

Studying Tetralogy of Fallot

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The University of Hong Kong
Principal Investigator
Chun-Ka Dr Wong, Clinical Assistant Professor
The University of Hong Kong/ Department of Medicine, Queen Mary Hospital
Intervention
SGLT2 inhibitor (Dapagliflozin 10mg)(drug)
Enrollment
106 enrolled
Eligibility
18 years · All sexes
Timeline
20252026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06668389 on ClinicalTrials.gov

Other trials for Tetralogy of Fallot

Additional recruiting or active studies for the same condition.

See all trials for Tetralogy of Fallot

← Back to all trials